

## CLAIMS

1. A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity, comprising an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
2. A compound according to claim 1, wherein at least one amino acid, naturally occurring in wild type IL4 at any one of positions 120 to 128 inclusive, is replaced by a different natural amino acid.
3. A compound according to claim 2, wherein the tyrosine naturally occurring at position 124 is replaced by a different natural amino acid.
4. A compound according to claim 3, wherein the tyrosine naturally occurring at position 124 is replaced by aspartic acid.
5. A compound according to claim 1, wherein the immunoglobulin is of the IgG subclass
6. A compound according to claim 5, wherein the constant domain(s) or fragment thereof is the whole or a substantial part of the constant region of the heavy chain of human IgG.
7. A compound according to claim 5, wherein the constant domain(s) or fragment thereof is the whole or a substantial part of the constant region of the heavy chain of human IgG4.
8. A compound according to claim 1, having the amino acid sequence represented by SEQ ID No:4, SEQ ID No:7 or SEQ ID No:10.
9. A process for preparing a compound according to claim 1, which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.

10. A process according to claim 9, which comprises:

- i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said compound;
- ii) transforming a host cell with said vector;
- 5 iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and
- iv) recovering said compound.

10 11. A DNA polymer comprising a nucleotide sequence that encodes a compound according to claim 1.

12. A DNA polymer according to claim 11, which comprises or consists of the sequence of SEQ ID No:3, SEQ ID No:6 or SEQ ID No:9.

15 13. A replicable expression vector comprising a DNA polymer according to claim 11.

14. A host cell transformed with a replicable expression vector according to claim 13.

20 15 A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

16. A method of treating conditions resulting from undesirable actions of IL4 and/or IL13 which comprises administering to the sufferer an effective amount of a compound according to claim 1.